One day many years ago, I found myself stuck in traffic and noticed a peculiar sign. It said something about the construction that was going on — the very thing that was hampering my commute.
It said all this construction was being funded by a bond. This was before I had ever started my career in finance, so bonds were an unfamiliar thing. But when I began my investment career, I soon realized that I could actually invest in these things. And the more I learned, the more I was ecstatic.
After all, If you can’t beat ’em, might as well make money off them…
You see, these types of bonds have a name — general obligation bonds — a type of municipal, or “muni” bond for short. These bonds are used for everything from helping fund road construction to building schools, bridges, water infrastructure and other public buildings. As I became more familiar with municipal bonds, I quickly became a fan. In fact, in my experience, muni-bonds are one of the safest ways for investors to earn income in today’s market — while also beating the tax man. (More on that in a moment.)
Top Safest Stocks To Invest In 2023: Danaos Corporation(DAC)
Danaos Corporation is an international owner of containerships, chartering its vessels to many of the world’s largest liner companies. We are a corporation domesticated in the Republic of The Marshall Islands on October 7, 2005, under the Marshall Islands Business Corporations Act, after having been incorporated as a Liberian company in 1998 in connection with the consolidation of our assets under Danaos Holdings Limited. In connection with our domestication in the Marshall Islands we changed our name from Danaos Holdings Limited to Danaos Corporation. Our manager, Danaos Shipping Company Limited, or Danaos Shipping, was founded by Dimitris Coustas in 1972 and since that time it has continuously provided seaborne transportation services under the management of the Coustas family. Dr. John Coustas, our chief executive officer, assumed responsibility for our management in 1987. Dr. Advisors’ Opinion:
- [By Shane Hupp]
Several large investors have recently bought and sold shares of the business. Royal Bank of Scotland Group PLC purchased a new stake in shares of Danaos during the third quarter worth $42,286,000. Greenwich Wealth Management LLC purchased a new stake in shares of Danaos during the fourth quarter worth $393,000. Renaissance Technologies LLC lifted its position in shares of Danaos by 209.5% during the third quarter. Renaissance Technologies LLC now owns 284,320 shares of the shipping company’s stock worth $341,000 after acquiring an additional 192,456 shares in the last quarter. O Shaughnessy Asset Management LLC purchased a new stake in shares of Danaos during the third quarter worth $176,000. Finally, Acadian Asset Management LLC purchased a new stake in shares of Danaos during the third quarter worth $112,000. Hedge funds and other institutional investors own 17.85% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Danaos (DAC) Announces Quarterly Earnings Results, Beats Estimates By $0.05 EPS” was published by Ticker Report and is the property of of Ticker Report. If you are viewing this story on another domain, it was stolen and republished in violation of United States and international copyright law. The original version of this story can be accessed at www.tickerreport.com/banking-finance/4168528/danaos-dac-announces-quarterly-earnings-results-beats-estimates-by-0-05-eps.html.
About Danaos
- [By Motley Fool Transcribers]
Danaos Corp (NYSE:DAC)Q4 2018 Earnings Conference CallFeb. 20, 2019, 9:00 a.m. ET
Contents:
Prepared Remarks Questions and Answers Call Participants
Prepared Remarks:Operator
Top Safest Stocks To Invest In 2023: Galapagos NV(GLPG)
Galapagos NV, a clinical stage biotech company, develops and commercializes novel medicines in Belgium, Croatia, France, and the Netherlands. The company is developing filgotinib, which has completed Phase 2 clinical trial for the treatment of rheumatoid arthritis and Crohns disease; GLPG1837, which is in Phase 2 clinical program, as well as GLPG2222, which is in Phase 1 clinical trial for treatment of cystic fibrosis mutations; and GLPG1690, which has completed Phase 1 clinical trial for the treatment of idiopathic pulmonary fibrosis. It is also developing GLPG1972, which is in Phase 1 clinical trial for the treatment of osteoarthritis; MOR106, which is in pre-clinical stage for the treatment of inflammatory diseases; and GLPG2665, a pre-clinical candidate for cystic fibrosis. The company has collaboration agreement with Gilead Sciences, Inc. for the development of filgotinib for inflammatory indications; and with Servier to develop GLPG1972. Galapagos NV was founded in 1999 and is headquartered in Mechelen, Belgium.
